(24), they evaluated cellular and humoral immune responses to EBV encoded antigens in patients with MS before and 1 year after interferon-beta treatment by ELISA and flow cytometry; although clinically effective interferon-beta therapy was associated with a downregulation of proliferative T cell responses to the latent EBNA-1, EBNA1-specific IgG responses as well as cellular and humoral immune responses to MHC class I restricted EBV antigens expressed during lytic replication and viral B cell transformation were similar before and after interferon-beta therapy. Here, IFNB1 is linked to myeloid sarcoma.